{"version":"1.0","type":"rich","provider_name":"Buzzsprout","provider_url":"https://www.buzzsprout.com","author_url":"https://www.asxbriefs.au/2335647","width":500,"thumbnail_width":600,"thumbnail_height":600,"title":"FIREBRICK PHARMA (FRE) - Combating the Common Cold: Firebrick Pharma's Executive Chairman Dr. Peter Molloy on Nasodine's Revolutionary Nasal Spray and Global Market Strategy","author_name":"ASX BRIEFS","html":"<iframe src=\"https://www.asxbriefs.au/2335647/episodes/15261393-firebrick-pharma-fre-combating-the-common-cold-firebrick-pharma-s-executive-chairman-dr-peter-molloy-on-nasodine-s-revolutionary-nasal-spray-and-global-market-strategy?client_source=oembed&amp;iframe=true\" width=\"100%\" height=\"200\" frameborder=\"0\" scrolling=\"no\" loading=\"lazy\" title=\"ASX BRIEFS, FIREBRICK PHARMA (FRE) - Combating the Common Cold: Firebrick Pharma&#39;s Executive Chairman Dr. Peter Molloy on Nasodine&#39;s Revolutionary Nasal Spray and Global Market Strategy\"></iframe>","height":200,"thumbnail_url":"https://www.asxbriefs.au/rails/active_storage/representations/redirect/eyJfcmFpbHMiOnsiZGF0YSI6MTExODY0Njk5LCJwdXIiOiJibG9iX2lkIn19--4950efcd19cc31898dfe84e6ee734b99c57f64b9/eyJfcmFpbHMiOnsiZGF0YSI6eyJmb3JtYXQiOiJqcGciLCJyZXNpemVfdG9fZmlsbCI6WzYwMCw2MDAseyJjcm9wIjoiY2VudHJlIn1dLCJzYXZlciI6eyJxdWFsaXR5Ijo2MH0sImNvbG91cnNwYWNlIjoic3JnYiJ9LCJwdXIiOiJ2YXJpYXRpb24ifX0=--0b154cb6b88107719b1a277923d35676ba5519cc/asx%20briefs.jpg"}